Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Glyn B. Steventon"'
Autor:
Glyn B. Steventon, Stephen C. Mitchell
Publikováno v:
Xenobiotica. 51:865-870
S-Carboxymethyl-l-cysteine is a mucolytic agent used as adjunctive therapy in the treatment of respiratory disorders. Various mechanisms of action have been proposed but few studies have attempted to link the required in vitro concentrations with tho
Autor:
Glyn B. Steventon, Stephen C. Mitchell
Publikováno v:
Drug metabolism and personalized therapyReferences. 37(4)
Autor:
Stephen C. Mitchell, Glyn B. Steventon
Publikováno v:
Xenobiotica. 50:51-63
1. Consistent differences in the proportion of an orally administered dose of S-carboxymethyl-l-cysteine subsequently excreted in the urine as S-oxide metabolites were reported 40 years ago. This observation suggested the existence of inter-individua
Autor:
Stephen C. Mitchell, Glyn B. Steventon
Publikováno v:
Current Drug Metabolism. 19:1130-1137
Background Although it is believed widely that the various routes of xenobiotic metabolism are now all known and effectively understood, occasionally there emerges a metabolite that signals a novel biotransformation pathway, especially where the xeno
Autor:
Stephen C. Mitchell, Glyn B. Steventon
Publikováno v:
Medical Hypotheses. 118:29-33
The S-oxidation of S-carboxymethyl-l-cysteine has been reported previously to be a biomarker of disease susceptibility in Parkinson's disease and Amyotrophic lateral sclerosis. In this investigation, the original observations have been confirmed with
Autor:
V. Kümmerlen, P. Mehlitz, L. Rohde, N. Utku, M. Knoedler, M. Machacek, M. Lassus, P. Treasure, Glyn B. Steventon, Konrad Klinghammer, Alexander Schmittel, U. Keilholz
Publikováno v:
European Journal of Cancer. 80:14-25
Aim An open-label, phase I dose-escalation trial was performed in adult patients with various solid cancers to identify the maximum tolerated dose (MTD), to assess the safety, pharmacokinetic profile and anti-tumour activity of the new prodrug CAP7.1
Publikováno v:
Drug metabolism and personalized therapy. 34(2)
Background The S-oxidation of S-carboxymethyl-L-cysteine has been reported previously to be a biomarker of disease susceptibility in Parkinson’s disease and amyotrophic lateral sclerosis. In the present investigation, the original observations have
Autor:
Stephen C. Mitchell, Glyn B. Steventon
Publikováno v:
Medical hypotheses. 121
Autor:
Glyn B. Steventon, Stephen C. Mitchell
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 49(4)
Mice that were heterozygous dominant for the enu1 and enu2 mutation in phenylalanine monooxygenase/phenylalanine hydroxylase (PAH) resulted in hepatic PAH assays for S-carboxymethyl-L-cysteine (SCMC) that had significantly increased calculated K
Autor:
Glyn B. Steventon, Stephen C. Mitchell
Publikováno v:
Xenobiotica. 50:1-2
“Ut quod aliis cibus est aliis fuat acre venenum”Titus Lucretius Carus (c.94-55 BC) “De Rerum Natura”, Book 4, line 638.We are all aware of this adage, loosely translated and oft-quoted as, “what i...